Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study

被引：0
|
作者：
Moore, Kathleen N.
Sabanathan, Dhanusha
Du, Yiqun
Duan, Huaxin
Li, Xiumin
Wang, Feng
Marathe, Omkar
Yang, Hua
Makker, Vicky
Growdon, Whitfield
Coward, Jim
Zhao, Peng
Liu, Liming
Shi, Rong
Liu, Shengxue
Gu, Wei
Qiu, Yang
Zhu, Zhongyuan
Zhang, Jian
Hamilton, Erika P.
机构：
[1] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Macquarie Univ, Canc Inst, Sydney, Australia
[3] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China
[4] Hunan Prov Peoples Hosp, Changsha, Peoples R China
[5] Linyi Canc Hosp, Shandong, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[7] Inst Oncol, Lakewood, CA USA
[8] Hebei Univ, Affiliated Hosp, Baoding, Hebei, Peoples R China
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Weill Cornell Med Coll, New York, NY USA
[11] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[12] ICON Canc Ctr, Brisbane, Australia
[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[14] Dual Biol, Philadelphia, PA USA
[15] Dual Biol, Princeton, NJ USA
[16] Dual Biol, Shanghai, Peoples R China
[17] Dual Biol, Basking Ridge, NJ USA
[18] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China
[19] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
[20] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3023
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Chen, Lei
    Tolcher, Anthony
    Gabrail, Nashat
    Barve, Minal
    Wu, Xiaohua
    Zhang, Jian
    Shi, Michael
    Qi, Chuan
    Yu, Steven
    Yao, Jenny
    Wang, Jianming
    Cavanaugh, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802
  • [32] A first-in-human, multicenter, phase 1/2, open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solid tumors
    McKean, Meredith
    Powderly, John D.
    Duncan, Meghan
    Norman, Teleen
    Patel, Ekta
    O'Neil, Jennifer
    Lee, George
    Luptakova, Katarina
    Kaufman, Howard E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [34] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [35] A Multicenter, Open-Label Phase 1 Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Advanced Solid Tumors
    Zhang, Jun
    Chavez, Jorge
    Chan, Nancy
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E27 - E27
  • [36] Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
    Patel, Manish R.
    Falchook, Gerald Steven
    Wang, Judy Sing-Zan
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Motlagh, Pejvack
    Miah, Kowser
    Mugundu, Ganesh M.
    Jones, Suzanne Fields
    Spigel, David R.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
    Richardson, Gary Edward
    Al-Rajabi, Raed
    Uprety, Dipesh
    Hamid, Anis
    Williamson, Stephen K.
    Baranda, Joaquina
    Mamdani, Hirva
    Lee, Ya-Li
    Li, Li
    Wang, Xingli
    Dong, Xunwei
    CANCERS, 2023, 15 (09)
  • [38] A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors
    Trarbach, T.
    Drevs, J.
    Strumberg, D.
    Gauler, T. C.
    Schneider, V.
    Eberhardt, W. E.
    Marotti, M.
    Puchalski, T. A.
    Swaisland, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
    Bechter, Oliver
    Loquai, Carmen
    Champiat, Stephane
    Baurain, Jean Francois
    Grob, Jean-Jacques
    Utikal, Jochen
    Rottey, Sylvie
    Berrocal, Alfonso
    Hassel, Jessica
    Arance, Ana
    Sanmamed, Miguel F.
    Boers-Sonderen, Marye
    Gastman, Brian
    Gebhardt, Christoffer
    Delafontaine, Brant
    Sahin, Ugur
    Tureci, Ozlem
    Abbadessa, Giovanni
    Di Genova, Gianfranco
    Brueck, Patrick
    Marpadga, Rahul
    Lee, Helen
    Lebbe, Celeste
    CANCER RESEARCH, 2023, 83 (08)
  • [40] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika P.
    Mathews, Cara Amanda
    Chu, Christina
    Diamond, Jennifer Robinson
    Hays, John L.
    Arend, Rebecca Christian
    Cristofanilli, Massimo
    Jewell, Andrea
    Reichmann, William
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Richardson, Debra L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345